Teleflex/$TFX
1D1W1MYTD1Y5YMAX
Capital at risk
About Teleflex
Teleflex Inc is a provider of medical technology products focused on enhancing clinical benefits, improving patient and provider safety and reducing total procedural costs. It designs, develops, manufactures and supply medical devices used by hospitals and healthcare providers supporting high-acuity emergent procedures. The company has three reportable segments: Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). It derives maximum revenue from Americas. Its products includes: Anaesthesia, Emergency Medicine, Interventional Cardiology/Radiology, Interventional Urology - UroLift System, Surgery, Urology, and Vascular Access.
- Ticker
- $TFX
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 15,500
- Headquarters
- Wayne, United States
- Website
- www.teleflex.com
Teleflex Metrics
BasicAdvanced
$5.5B
-
-$23.41
0.81
$1.02
1.05%
Price and volume
Market cap
$5.5B
Beta
0.81
52-week high
$145.00
52-week low
$100.18
Average daily volume
634K
Dividend rate
$1.02
Financial strength
Current ratio
2.604
Quick ratio
0.956
Long term debt to equity
0.959
Total debt to equity
0.989
Interest coverage (TTM)
1.89%
Profitability
EBITDA (TTM)
403.903
Gross margin (TTM)
55.11%
Net profit margin (TTM)
-45.76%
Operating margin (TTM)
9.54%
Effective tax rate (TTM)
60.58%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
1.90%
Return on equity (TTM)
-0.70%
Valuation
Price to revenue (TTM)
2.522
Price to book
1.88
Price to tangible book (TTM)
-6.53
Price to free cash flow (TTM)
17.384
Free cash flow yield (TTM)
5.75%
Free cash flow per share (TTM)
7.422
Dividend yield (TTM)
0.79%
Forward dividend yield
1.05%
Growth
Revenue change (TTM)
110.94%
Earnings per share change (TTM)
-660.80%
3-year revenue growth (CAGR)
-8.04%
10-year revenue growth (CAGR)
2.18%
3-year earnings per share growth (CAGR)
44.27%
10-year earnings per share growth (CAGR)
15.31%
What the Analysts think about Teleflex
Analyst ratings (Buy, Hold, Sell) for Teleflex stock.
Analyst projections of the future price of Teleflex stock.
Bulls say / Bears say
Teleflex’s Q2 2026 revenue rose 28.9% year-over-year to $570.3 million and pro forma adjusted constant currency revenue was up 4.7%, driven by strong Vascular and Surgical segment performance (SEC).
On August 3, 2026, Teleflex completed the strategic divestiture of its OEM business for $1.5 billion in cash, generating approximately $1.25 billion of after-tax proceeds to pay down $800 million of debt and fund its $1 billion share repurchase program, enhancing financial flexibility and shareholder returns (SEC).
On July 29, 2026, the FDA granted BLA approval for EZPLAZ™ Freeze Dried Plasma—the first FDA-licensed freeze-dried plasma product in the U.S.—broadening Teleflex’s emergency medicine portfolio with a room-temperature stable plasma solution (FDA).
Teleflex reduced its full-year 2026 pro forma adjusted constant currency revenue growth outlook to 3.50%–4.50% from 4.50%–5.50%, reflecting extended integration delays of its Vascular Intervention acquisition, signalling near-term top-line headwinds (Business Wire).
Teleflex is undergoing a leadership transition with the appointment of Jason Weidman as President and CEO effective June 8, 2026, which may introduce execution risks during the organisational changeover (Business Wire).
On May 26, 2026 Teleflex entered into a new credit agreement providing a $1.0 billion revolving facility and $1.2 billion of term loans, increasing leverage and exposing the company to higher fixed-charge obligations amid rising interest rates (Reuters).
Data summarised monthly by Lightyear AI. Last updated on 8 Sept 2026.
Teleflex Financial Performance
Revenues and expenses
Teleflex Earnings Performance
Company profitability
Upcoming events
Teleflex News
AllArticlesVideos
Teleflex Appoints Veteran Medical Technology Executive Sean M. Salmon to Teleflex Board of Directors
Business Wire1 week ago
Teleflex Features Innovative Dynetic™-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
Business Wire2 weeks ago
Teleflex Q2 Earnings Call Highlights
MarketBeat1 month ago
Funds containing Teleflex
AllUSDGBPEUR
Fund name | Fund size | $TFX weighting |
|---|---|---|
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.33% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.33% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.14% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.14% |
iShares MSCI World Small Cap$WSML | $9B | 0.05% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.